The research and scientific communities are evolving in real time during what is arguably one of the most technologically transformative periods in modern history. Artificial intelligence (AI) is reshaping how researchers identify patterns in data, and computational models can increasingly predict structures and relationships in ways that would have seemed like science fiction only a few years ago.

Those themes were on full display at this year's American Society of Pharmacognosy (ASP) Annual Meeting, where discussions highlighted the growing role of AI in natural products discovery, including its ability to predict antibiotic and metabolite structures before traditional isolation chemistry begins.

For many attendees, a clear takeaway was just how quickly scientific discovery is accelerating. But for Kirk Maxey, President and CEO of Cayman Chemical, the meeting also reinforced a different observation.

Despite decades of technological advancement, some of the most important aspects of scientific discovery remain unchanged.

"What struck me was the increasing ability of researchers to predict structures and relationships before doing the classical chemistry," says Maxey. "The technology is remarkable. But it can't escape the foundational importance of someone, somewhere, actually putting together the structure, atom by atom. That's still where scientific confidence comes from."

It's a perspective shaped by experience. Over the course of more than four decades in the life sciences, Maxey has witnessed wave after wave of technological innovation. New analytical methods, automation, high-throughput screening, genomics, proteomics, metabolomics, and now artificial intelligence have, one-by-one, come to the forefront with promises to accelerate discovery and reshape the future of science and medicine. And in many ways, they've succeeded.

Yet history suggests that every major advance creates a similar challenge of ensuring that speed doesn't outpace certainty.

"Science has always evolved through better tools," Maxey points out. "What changes are the capabilities, but what doesn't change is the need to know whether the answer is actually correct."

As AI becomes increasingly integrated into research workflows, the ability to generate hypotheses is accelerating. Researchers can move faster and explore more possibilities. They can analyze larger and more complex datasets at scale, and the number of potential opportunities coming from this analysis is speeding up exponentially. As a result, the bottleneck is shifting from generating ideas to determining which ideas are true and can be proven in the real world.

AI may help researchers identify where to look, or lead them to interesting investigational paths more quickly, but as Maxey points out, "Prediction and proof are not the same thing. At the end of the day, scientific progress requires validation."

This truth extends beyond natural products research.

At a time when public confidence in institutions, including scientific institutions, faces increasing pressure, Maxey believes the scientific community must remain focused on the principles that have always underpinned trustworthy research. Rigor, reproducibility, transparency, and a willingness to follow the evidence wherever it leads.

The challenge is that trust is often built through work that remains largely invisible to everyone except the scientists doing it. Things like well-characterized reference standards and carefully validated methods help create results that can be reproduced by another researcher years later, but these are rarely the most celebrated parts of scientific discovery. Even if they are often what determines whether a finding stands the test of time.

The scientific breakthroughs that make headlines are the result of countless decisions made long before publication. The quality controls, the experimental design, the commitment to getting the answer right… these are the decisions that form the foundation supporting every credible advancement. And those fundamentals only become more important as scientific tools and technologies grow more sophisticated.

"The irony is that the more powerful our technologies become, the more important scientific judgment becomes," says Maxey. "If AI allows us to generate 10x more hypotheses, then our ability to validate and trust those results becomes even more valuable."

AI will undoubtedly continue to transform discovery, and computational tools will only become more capable. Data generation will continue to accelerate. Future ASP meetings will almost certainly showcase advances that seem extraordinary by today's standards. But through all of this, the core responsibility of science will remain the same. To pursue answers that are not only interesting (or promising), but correct.

"The tools will continue to change," Maxey points out. "They should. That's how progress happens. But science ultimately depends on trust. And trust is still built the way it's always been built. Through the last four decades, through every change in scientific knowledge and capability, that's one thing I've never seen change."

Having spent decades helping researchers navigate periods of extraordinary scientific change, Maxey understands that today's AI revolution is unlikely to be the last technology to transform discovery. Through every wave of innovation, Cayman Chemical has sought to provide researchers with the quality and reliability they need to stand behind their work with confidence. As much as the technologies may change, the principles behind trustworthy science do not. And for Cayman, that commitment to scientific integrity has never been more relevant, it seems, than it is today.